BioAdaptives Inc.
Other OTCCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- James Keener
- Full Time Employees
- 1
- Sector
- Healthcare
- Industry
- Medical - Pharmaceuticals
- Address
- 2620 Regatta Drive Las Vegas NV United States of America 89128
- IPO Date
- Jun 1, 2016
- CIK
- 0001575142
- Website
- shopbioadaptives.com
- Similar Companies
- Business
- BioAdaptives, Inc. (OTC: BDPT) investigates, markets, and distributes natural plant, algal, and mushroom-based nutraceutical products and medical devices for humans and animals; core offerings include dietary supplements such as Zeranovia, a proprietary nutrient-optimizing ingredient for weight management and enhanced bioavailability in foods and beverages; Xcellara and PawPa for muscle and tissue repair, regeneration, and pet wellness; MyndMed, a nootropic for cognition, focus, memory, sleep improvement, and fatigue reduction; PluriPain, PrimiSleep, PrimiLungs, and PrimiCell for pain relief, sleep, lung health, and cellular wellness; Lung Flute, a respiratory medical device; equine products like Equine-in-One and uriP; and AI-driven FYO app for body composition analysis via smartphone photos. The company operates in the biotechnology and wellness sectors, targeting consumers, holistic healthcare practitioners, fitness professionals, sports teams, and pet owners with products addressing pain relief, immune support, antiviral activity, stress resistance, endurance, recovery, anti-aging, and weight control. Founded in 2013 and headquartered in Las Vegas, Nevada, BioAdaptives conducts human clinical trials and sources ingredients globally using proprietary enhancement techniques. In November 2024, the company announced a complete product overhaul, launching a redesigned lineup of next-generation nutraceuticals including enhanced weight management solutions that preserve muscle while targeting fat loss, advanced muscle repair, anti-aging formulations for humans, and Paw Partners pet products, incorporating customer feedback, rigorous testing, sustainability practices, and superior performance metrics. Recent developments encompass the January 2024 signing of a non-exclusive distributor agreement with Pixelcando S.L. in Spain for the FYO AI body composition app, enabling U.S. promotion to consumers, gyms, spas, and healthcare providers in a market projected to reach $2.6 billion by 2030; the October 2025 commercial launch of MyndMed following successful pilot tests with 2025 sales contracts doubling 2024 levels; plans for Zeranovia commercial introduction and revenue generation in 2025 after promising dosage trials showing significant weight loss with minimal side effects; late 2024 rollout of "Nu" branded enhanced practitioner products with upgraded ingredients and dosing; a robust acquisition pipeline for market expansion; and January 2025 FINRA approval of a common stock dividend payable on January 22.
Company News
BioAdaptives Confirms First Commercial Orders of XcellaraHeart(TM) and Outlines Capital Restructuring Progress
UFC Hall of Famer Michael Bisping Joins BioAdaptives to Champion MyndSystem(TM)
BioAdaptives, Inc. Announces CEO's Share Cancellation and Provides Capital Restructure Update
BioAdaptives Inc. Introduces XcellaraHeart(TM): the World's First Stem Cell Mobilizer with a Targeted Cardiac Homing Signal
BioAdaptives Inc. Opens Commercial Ordering Window for XcellaraHeart(TM) Cellular Wellness Formula
BioAdaptives Inc. Eliminates Major Market Overhang by Retiring the Debt of the Largest Convertible Commercial Investor
BioAdaptives Inc. Reports Scaling of E-Commerce Footprint and Consumer Reach for MyndSystem(TM) Nootropic Platform
BioAdaptives Inc. Announces Operational Readiness and Completion of the Commercial Supply Chain for Upcoming Product Launches
BioAdaptives® Outlines Xcellara™ Platform Strategy: Integrating Stem Cell Supply and Direction for Targeted Wellness
BioAdaptives® Inc. Announces XcellaraHeart™, a Cardiovascular Wellness Formula Built on Xcellara's Human-Clinical Data Demonstrating a 268.8% Increase in Circulating Stem/Progenitor-Type Cells
BioAdaptives Completes MyndSystem™ Platform with TruShield Certification of MyndRenew™, Securing Full WADA Compliance for Professional Athletes and Expanding Market Opportunity
BioAdaptives Launches MyndSystem™ Website — The First Supplement Platform Designed to Support Both Daytime Cognitive Performance and Overnight Brain Recovery
BioAdaptives, Inc. Launches MyndRenew™ to Complete the 24-Hour Brain Performance Cycle
BioAdaptives® Announces Commercial Launch of MyndMed™ Following Successful Pilot Testing
BioAdaptives' MyndMed™ Receives Full Clearance from TruShield™, Meeting UFC and WADA Standards for Athlete Safety
BioAdaptives Announces National Launch of NeuroRush™ — A Cutting-Edge Adaptogenic Nootropic for Mental Clarity, Focus, and Resilience
BioAdaptives Announces National Launch of Pawpa™ Regen
BioAdaptives® PawPa™ Regen Provides Breakthrough Stem Cell Support for Pets, Backed by Clinically Proven APBAR® Scale Improvements
Zeranovia(TM) Weight Loss Product Shows Promising Results in Dosage Trial
BioAdaptives Welcomes UFC Senior Executive Reed Harris to Its Board of Advisors